α7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia

被引：46
|
作者：
Ishikawa, Masatomo [1 ]
Hashimoto, Kenji [1 ]
机构：
[1] Chiba Univ, Ctr Forens Mental Hlth, Div Clin Neurosci, Chiba 2608670, Japan
来源：
CURRENT PHARMACEUTICAL DESIGN | 2011年 / 17卷 / 02期
关键词：
alpha 7 nicotinic acetylcholine receptors; schizophrenia; smoking; nicotine; P50 auditory evoked potential suppression; agonists; allosteric modulators; VITRO PHARMACOLOGICAL CHARACTERIZATION; POSITIVE ALLOSTERIC MODULATOR; INDUCED COGNITIVE DEFICITS; REPEATED AUDITORY-STIMULI; IN-VIVO CHARACTERIZATION; MIDBRAIN DOPAMINE AREAS; CIGARETTE-SMOKING; P50; SUPPRESSION; PARTIAL AGONIST; DBA/2; MICE;
D O I：
10.2174/138161211795049561
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Accumulating evidence suggests that the alpha 7 subtype of nicotinic acetylcholine receptors (nAChRs) plays a role in the pathophysiology of schizophrenia. Deficits in auditory P50 evoked potential suppression in patients with schizophrenia are associated with decreased density of alpha 7 nAChRs in the brain. Some agonists (e. g., DMXB-A and tropisetron) at alpha 7 nAChRs can improve P50 deficits in patients with schizophrenia. Together, these findings indicate that alpha 7 nAChRs are a potential therapeutic target for schizophrenia. Currently, a number of agonists and allosteric modulators at alpha 7 nAChRs are under development as potential therapeutic drugs. In this article, we review recent topics on alpha 7 nAChR agonists and alpha 7 nAChR allosteric modulators as therapeutic drugs for schizophrenia.
引用
收藏
页码：121 / 129
页数：9
相关论文
共 50 条
  • [41] Cortical parvalbumin GABAergic deficits with α7 nicotinic acetylcholine receptor deletion: implications for schizophrenia
    Lin, Hong
    Hsu, Fu-Chun
    Baumann, Bailey H.
    Coulter, Douglas A.
    Anderson, Stewart A.
    Lynch, David R.
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2014, 61 : 163 - 175
  • [42] The α7 nicotinic acetylcholine receptor in schizophrenia:: decreased mRNA levels in peripheral blood lymphocytes
    Perl, O
    Ilani, T
    Strous, RD
    Lapidus, R
    Fuchs, S
    FASEB JOURNAL, 2003, 17 (11): : 1948 - +
  • [43] Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia
    Young, Jared W.
    Geyer, Mark A.
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (08) : 1122 - 1132
  • [44] Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
    Hajos, Mihaly
    Rogers, Bruce N.
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (05) : 538 - 554
  • [45] Neuroimmune Interactions in Schizophrenia: Focus on Vagus Nerve Stimulation and Acetylcholine the Alpha-7 nicotinic Acetylcholine Receptor
    das Gracas Corsi-Zuelli, Fabiana Maria
    Brognara, Fernanda
    da Silva Quirino, Gustavo Fernando
    Hiroki, Carlos Hiroji
    Fais, Rafael Sobrano
    Del-Ben, Cristina Marta
    Ulloa, Luis
    Salgado, Helio Cesar
    Kanashiro, Alexandre
    Loureiro, Camila Marcelino
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [46] The spirooxazolidinone moiety as a potential substrate for selective agonists at the α7 nicotinic acetylcholine receptor
    Barrett, D
    Barlocco, D
    DRUG DISCOVERY TODAY, 2001, 6 (05) : 270 - 271
  • [47] α7 nicotinic acetylcholine receptor in memory processing
    Pastor, Veronica
    Medina, Jorge H.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2024, 59 (09) : 2138 - 2154
  • [48] The α7 nicotinic acetylcholine receptor in neuronal plasticity
    Ron S. Broide
    Frances M. Leslie
    Molecular Neurobiology, 1999, 20 : 1 - 16
  • [49] Allosteric modulators of the α7 nicotinic acetylcholine receptor
    Faghih, Ramin
    Gopalakrishnan, Murali
    Briggs, Clark A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (04) : 701 - 712
  • [50] Selective α7 nicotinic acetylcholine receptor ligands
    Mazurov, Anatoly
    Hauser, Terry
    Miller, Craig H.
    CURRENT MEDICINAL CHEMISTRY, 2006, 13 (13) : 1567 - 1584
12345